These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38720458)

  • 21. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
    Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
    Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of Potent and Controllable Anticoagulants Using DNA Aptamers and Nanostructures.
    Rangnekar A; Nash JA; Goodfred B; Yingling YG; LaBean TH
    Molecules; 2016 Feb; 21(2):. PubMed ID: 26861277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new anticoagulant-antidote pair: control of thrombin activity by aptamers and porphyrins.
    Joachimi A; Mayer G; Hartig JS
    J Am Chem Soc; 2007 Mar; 129(11):3036-7. PubMed ID: 17319665
    [No Abstract]   [Full Text] [Related]  

  • 24. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer.
    Musumeci D; Montesarchio D
    Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
    Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
    Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA-Nanoscaffold-Assisted Selection of Femtomolar Bivalent Human α-Thrombin Aptamers with Potent Anticoagulant Activity.
    Zhou Y; Qi X; Liu Y; Zhang F; Yan H
    Chembiochem; 2019 Oct; 20(19):2494-2503. PubMed ID: 31083763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive Allosteric Modulation of Antithrombin's Inhibitory Activity by RNA Aptamers.
    Zaman K; Breitman A; Malik I; Fortenberry YM
    Nucleic Acid Ther; 2023 Aug; 33(4):277-286. PubMed ID: 37093131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid Complexation of Aptamers by Their Specific Antidotes.
    Stoll H; Steinle H; Wilhelm N; Hann L; Kunnakattu SJ; Narita M; Schlensak C; Wendel HP; Avci-Adali M
    Molecules; 2017 Jun; 22(6):. PubMed ID: 28594360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New High-Affinity Thrombin Aptamers for Advancing Coagulation Therapy: Balancing Thrombin Inhibition for Clot Prevention and Effective Bleeding Management with Antidote.
    Ayass MA; Griko N; Pashkov V; Tripathi T; Zhang J; Ramankutty Nair R; Okyay T; Zhu K; Abi-Mosleh L
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
    Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
    Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
    Kretz CA; Cuddy KK; Stafford AR; Fredenburgh JC; Roberts R; Weitz JI
    Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Research Progress of Direct Thrombin Inhibitors.
    Sun ZG; Yang-Liu ; Zhang JM; Cui SC; Zhang ZG; Zhu HL
    Mini Rev Med Chem; 2020; 20(16):1574-1585. PubMed ID: 31644402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
    Sheffield WP; Lambourne MD; Eltringham-Smith LJ; Bhakta V; Arnold DM; Crowther MA
    J Thromb Haemost; 2014 Jul; 12(7):1110-5. PubMed ID: 24815541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aptamer RA36 inhibits of human, rabbit, and rat plasma coagulation activated with thrombin or snake venom coagulases.
    Savchik EY; Kalinina TB; Drozd NN; Makarov VA; Zav'yalova EG; Lapsheva EN; Mudrik NN; Babij AV; Pavlova GV; Golovin AV; Kopylov AM
    Bull Exp Biol Med; 2013 Nov; 156(1):44-8. PubMed ID: 24319726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of target-specific oral anticoagulants.
    Siegal DM; Cuker A
    Drug Discov Today; 2014 Sep; 19(9):1465-70. PubMed ID: 24880102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA aptamers for human thrombin with high anticoagulant activity demonstrate target- and species-specificity.
    Zavyalova E; Golovin A; Timoshenko T; Babiy A; Pavlova G; Kopylov A
    Curr Med Chem; 2012; 19(30):5232-7. PubMed ID: 22934762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptameric hirudins as selective and reversible EXosite-ACTive site (EXACT) inhibitors.
    Yu H; Kumar S; Frederiksen JW; Kolyadko VN; Pitoc G; Layzer J; Yan A; Rempel R; Francis S; Krishnaswamy S; Sullenger BA
    Nat Commun; 2024 May; 15(1):3977. PubMed ID: 38730234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gold nanoparticles modified with self-assembled hybrid monolayer of triblock aptamers as a photoreversible anticoagulant.
    Huang SS; Wei SC; Chang HT; Lin HJ; Huang CC
    J Control Release; 2016 Jan; 221():9-17. PubMed ID: 26643617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production and Testing of RNA Origami Anticoagulants.
    Krissanaprasit A; Key C; Froehlich K; LaBean TH
    Methods Mol Biol; 2023; 2639():339-350. PubMed ID: 37166725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.